Bladder Cancer Treatment Dilemmas: The Cases You Face and What To Do about Them (2022)

CME Available: https://auau.auanet.org/node/36049

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Assign risk stratification to patients with bladder cancer.

2. Adapt treatment choices depending on risk of disease and availability of bacillus Calmette-Guérin (BCG).

3. Individualize patient surveillance needs.

4. Provide broadened treatment options beyond intravesical therapy.

Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022)

CME Available: https://auau.auanet.org/node/36044

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.

2. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

3. Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results.

4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

CME Available: https://auau.auanet.org/node/35725

Moderator: Jay D. Raman, MD, FACS

Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation).

2. Ask relevant questions about sexual practices that may impact the side effects that are of interest to them (partner with men, women and both and anal receptive vs. anal penetration sex).

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas

AstraZeneca

Bayer

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

Pfizer, Inc.

Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022)

CME Available: https://auau.auanet.org/node/36065

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma.

2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma.

3. Identify appropriate treatment options for management of complex cases.

Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2022)

CME Available: https://auau.auanet.org/node/36028

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for OAB.

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.

3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.

Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies

CME Available: https://auau.auanet.org/node/35160

Course Director: Jennifer Robles, MD, MPH

Faculty: Chad Brummett, MD; Gregory Auffenberg, MD, MS; Hitya Abraham, MD; Kevan Sternberg, MD

After participating in this activity, learners will be able to:

1. Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operative opioid prescribing.

2. Discuss multi-modal pain control and identify at least two non-opioid medications which can be used to manage post-operative pain and reduce post-operative opioid prescribing.

Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022)

CME Available: https://auau.auanet.org/node/36020

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC)

2. Recommend treatment for NMIBC based on risk stratification.

3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies.

4. Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management.

5. Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.

The Changing Face of Advanced Prostate Cancer 2022(2022)

CME Available: https://auau.auanet.org/node/36010

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival.

2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy.

3. Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival.

4. Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities.

5. Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.

Host: Jay D. Raman, MD, FACS

Guest: Akanksha Mehta, MD, MS

For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University

Diversity Equity and Inclusion in Urology: What Do We Need to Know?

CME Available: https://auau.auanet.org/node/35746

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify the different forms of racism and, more importantly, identify their own subconscious personal bias.

2. Identify the impact of race on medical education, research and clinical care.

3. Identify how DEI initiatives can positively impact the practice of urology.

4. Examine innovative methodologies employed to increase the numbers of underrepresented groups in urology.

5. Participate in activities to encourage and support individualism among urology team members.